Molecular and epidemiologic findings of childhood acute leukemia in costa rica

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 2, 2009, Pages 131-135

  Santamaría Quesada, Carlos ^a,b,e   Vargas, Mario ^a   Venegas, Patricia ^c   Calvo, Melvin ^a   Obando, Catalina ^c   Valverde, Berta ^d   Cartín, Walter ^c,d   Carrillo, Juan Manuel ^e   Jimenez, Rafael ^d   González, Marcos ^b  

^a Clinical Laboratory Department   (Costa Rica)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Cytogenetic Laboratory   (Costa Rica)

^d Clinical Laboratory Department   (Costa Rica)

^e National Children's Hospital   (Costa Rica)

Author keywords

Childhood acute leukemia; Costa Rica; Lowincome countries; Molecular biology

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; HOX PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN HOX11L2; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; ONCOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; COSTA RICA; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM REPEAT; ACUTE DISEASE; CHROMOSOME ANALYSIS; GENE REARRANGEMENT; GENETICS; LEUKEMIA; MUTATION;

ACUTE DISEASE; CHILD; COSTA RICA; CYTOGENETIC ANALYSIS; GENE REARRANGEMENT; HUMANS; LEUKEMIA; MUTATION; ONCOGENE PROTEINS, FUSION;

EID: 60849092946     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818c919e     Document Type: Article

References (32)

1. Parkin DM, Stiller CA, Draper GJ, et al. The international incidence of childhood cancer. Int J Cancer. 1988;42:511-520.
2. Pui CH, Schrappe M, Ribeiro RC, et al. Childhood and adolescent lymphoid and myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2004:118-145.
3. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342: 998-1006.
4. Maloney K, McGavran L, Murphy J, et al. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia. 1999;13:1708-1712.
5. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571-577.
6. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108:3654-3661.
7. Ribeiro R. Update on the management of pediatric acute promyelocytic leukemia. Clin Adv Hematol Oncol. 2006;4: 263-265.
8. Monge P, Wesseling C, Rodriguez AC, et al. Childhood leukaemia in Costa Rica, 1981 to 96. Paediatr Perinat Epidemiol. 2002;16:210-218.
9. Valsecchi MG, Tognoni G, Bonilla M, et al. Clinical epidemiology of childhood cancer in Central America and Caribbean countries. Ann Oncol. 2004;15:680-685.
10. Howard SC, Metzger ML, Wilimas JA, et al. Childhood cancer epidemiology in low-income countries. Cancer. 2007;112: 461-472.
11. Masera G, Baez F, Biondi A, et al. North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet. 1998;352:1923-1926.
12. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
13. Venegas P, Rivera J. Cytogenetic studies in children with acute lymphocytic leukemia-B in Costa Rica. Rev Biol Trop. 2004;52: 551-558.
14. Mitelman F. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
15. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol. 1998; 16:3774-3781.
16. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
17. Chillon MC, Fernandez C, Garcia-Sanz R, et al. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. Hematol J. 2004;5:239-246.
18. Ballerini P, Blaise A, Busson-Le CM, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood. 2002;100:991-997.
19. Gabert J, Beillard E, van der Velden V, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17: 2318-2357.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Instituto Costarricense de Estadistica y Censos. Available at: http://www.inec.go.cr/. Accessed on: March 29, 2008.
22. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
23. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992 to 2004). Cancer. 2008;112:416-432.
24. Mejia-Arangure JM, Bonilla M, Lorenzana R, et al. Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer. 2005;5:33.
25. Morera B, Barrantes R, Marin-Rojas R. Gene admixture in the Costa Rican population. Ann Hum Genet. 2003;67:71-80.
26. Monge P, Wesseling C, Guardado J, et al. Parental occupational exposure to pesticides and the risk of childhood leukemia in Costa Rica. Scand J Work Environ Health. 2007;33:293-303.
27. Aldrich MC, Zhang L, Wiemels JL, et al. Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev. 2006;15:578-581.
28. Steinbach D, Hermann J, Viehmann S, et al. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet. 2002;133: 118-123.
29. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106:1419-1422.
30. Douer D, Preston-Martin S, Chang E, et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;87:308-313.
31. Malta CA, Pacheco EC, Cantu RA, et al. Childhood acute promyelocytic leukemia in Nicaragua. Ann Oncol. 1993;4: 892-894.
32. Boza WB, Cruz GJ, Saenz MP, et al. High incidence of acute promyelocytic leukemia in the Caucasian population: the Costa Rica experience. Am J Hematol. 2004;76:96-97.